Cravatt Benjamin
Transaction: 06/01/2026
OTHER
Change
0
Price
Not reported
Filing
06/03/2026
Type
OTHER
Alnylam Pharmaceuticals, Inc.
ALNY • Biotechnology
$231.41
▲ +0.70 (+0.30%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$27.43B
Growth
—
Cash Flow
2/5
Trend
Volatile
Evidence
Positive revenue growth · 41.2%Positive free cash flow · 3.55Healthy liquidity · 2.76Expensive earnings multiple · 166.04
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$231.41
Change0.30%
Market Cap$27.43B
52W Range197.81 - 495.55
Beta0.27
Gross Margin81.77%
Oper. Margin13.51%
Profit Margin8.45%
Debt/Eq1.62
Current Ratio2.76
Quick Ratio2.71
Target$438.50
Price$231.41
Change0.30%
Market Cap$27.43B
52W Range197.81 - 495.55
Beta0.27
Gross Margin81.77%
Oper. Margin13.51%
Profit Margin8.45%
Debt/Eq1.62
Current Ratio2.76
Quick Ratio2.71
Target$438.50
Target Upside89.49%
Target Median$436.50
Target Range400.00 - 485.00
Volume9.75M
Avg Volume1.28M
EPS Surprise0.64
Investment DNA
How strong this company looks for long-term investors
64
out of 100
Business Quality
Margins, moat, returns
67/100
Financial Strength
Debt, cash, stability
62/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Positive revenue growth · 41.2%Positive free cash flow · 3.55Healthy liquidity · 2.76Expensive earnings multiple · 166.04
Analyst view
Analyst sentiment and price target
Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-07-31
Low
$400.00
Mean
$438.50
Median
$436.50
High
$485.00
Insider Transactions
Recent executive and insider activity
Cravatt Benjamin
Transaction: 06/01/2026
BUY
Change
+4,393
Price
$295.63
Filing
06/03/2026
Type
BUY
PYOTT DAVID E I
Transaction: 06/01/2026
SELL
Change
-3,830
Price
$70.20
Filing
06/03/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Cravatt Benjamin | OTHER | 0 | Not reported | 06/01/2026 | 06/03/2026 |
| Cravatt Benjamin | BUY | +4,393 | $295.63 | 06/01/2026 | 06/03/2026 |
| PYOTT DAVID E I | SELL | -3,830 | $70.20 | 06/01/2026 | 06/03/2026 |
| PYOTT DAVID E I | SELL | -17 | $302.65 | 06/01/2026 | 06/03/2026 |
| Arbuckle Stuart A | BUY | +671 | Not reported | 05/20/2026 | 05/22/2026 |
| Arbuckle Stuart A | BUY | +1,441 | $298.48 | 05/20/2026 | 05/22/2026 |
| Ausiello Dennis A | BUY | +1,441 | $298.48 | 05/20/2026 | 05/22/2026 |
| Ausiello Dennis A | BUY | +671 | Not reported | 05/20/2026 | 05/22/2026 |
| BRANDICOURT OLIVIER | BUY | +1,441 | $298.48 | 05/20/2026 | 05/22/2026 |
| BRANDICOURT OLIVIER | BUY | +671 | Not reported | 05/20/2026 | 05/22/2026 |
| HAMBURG MARGARET A | BUY | +1,441 | $298.48 | 05/20/2026 | 05/22/2026 |
| HAMBURG MARGARET A | BUY | +671 | Not reported | 05/20/2026 | 05/22/2026 |
| KELLOGG PETER N | BUY | +1,441 | $298.48 | 05/20/2026 | 05/22/2026 |
| KELLOGG PETER N | BUY | +671 | Not reported | 05/20/2026 | 05/22/2026 |
| PYOTT DAVID E I | BUY | +1,441 | $298.48 | 05/20/2026 | 05/22/2026 |
| PYOTT DAVID E I | BUY | +671 | Not reported | 05/20/2026 | 05/22/2026 |
| Reitan Colleen F | BUY | +1,441 | $298.48 | 05/20/2026 | 05/22/2026 |
| Reitan Colleen F | BUY | +671 | Not reported | 05/20/2026 | 05/22/2026 |
| SCHULMAN AMY W | BUY | +1,802 | $298.48 | 05/20/2026 | 05/22/2026 |
| SCHULMAN AMY W | BUY | +838 | Not reported | 05/20/2026 | 05/22/2026 |